{'fraction_non_alphanumeric': 0.02040816326530612, 'fraction_numerical': 0.0027829313543599257, 'mean_word_length': 6.145695364238411, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Insanovin aerosol therapy in the treatment of bronchial asthma].

Sixty-seven patients with bronchial asthma treated with the bronchodilator insanovin for 4 weeks were followed up. The efficiency of aerosol therapy with insanovin as the basic agent was determined by the time course of changes in the clinical manifestations of the disease, in external respiratory functional and immunological parameters. In patients with first-degree bronchial obstruction, 2 weeks of aerosol therapy were sufficient to normalize the clinical manifestations of the diseases and external respiratory functional and immunological parameters. In patients with second-degree bronchial obstruction, 4-week aerosol therapy produced an ever-increasing therapeutic effect, which affected external respiratory functional and immunological parameters. In patients with third-degree bronchial obstruction, aerosol therapy could cease fits of suffocation, retain insignificant dyspnea, diminish cough, and normalize nocturnal sleep with moderate external respiratory functional and immunological changes.